Pfizer to manufacture Gilead’s Covid-19 drug candidate remdesivir

Pfizer has signed a multi-year agreement with Gilead Sciences to manufacture and supply the latter’s investigational antiviral remdesivir for the treatment of Covid-19.

Under the deal terms, Pfizer will offer contract manufacturing services at its McPherson, Kansas facility for the manufacture and supply of remdesivir.

Earlier this year, Pfizer came out with a five-point plan, which sought all members of the innovation ecosystem, from large pharma firms to the smallest of biotech companies, from government agencies to academic institutions, to commit towards working together to address the Covid-19 health crisis.

Albert Bourla – Chairman and CEO of Pfizer said: “From the beginning it was clear that no one company or innovation would be able to bring an end to the COVID-19 crisis. Pfizer’s agreement with Gilead is an excellent example of members of the innovation ecosystem working together to deliver medical solutions.

“Together, we are more powerful than alone. As one of the largest manufacturers of vaccines, biologics and sterile injectables, it is a privilege to offer our expertise and infrastructure to help fight this pandemic. In that spirit, we are pleased that Gilead is using our manufacturing capacity to help facilitate supply of this medicine to patients as quickly as possible.”